Chembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022
Rhea-AI Summary
Chembio Diagnostics, Inc. (CEMI) will release its Q2 2022 financial results on August 4, 2022, after trading hours. The conference call for discussion will begin at 4:30 p.m. Eastern Time on the same day. Interested investors can access the call via phone or online. Chembio specializes in point-of-care diagnostics, particularly in infectious diseases, leveraging innovative DPP technology to enhance testing capabilities. The company's products are utilized globally across various healthcare settings.
Positive
- Focus on infectious disease diagnostics, a growing market.
- Innovative DPP technology enhances testing capabilities.
Negative
- None.
News Market Reaction – CEMI
On the day this news was published, CEMI declined 6.49%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAUPPAUGE, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 2022 after the close of trading on Thursday, August 4, 2022.
The company’s management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on August 4, 2022. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 558147 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US using passcode 45932 or by accessing www.chembio.com/investors/calendar-of-events/.
About Chembio Diagnostics
Chembio is a leading diagnostics company focused on developing and commercializing point-of-care tests used to detect and diagnose infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19 and other viral and bacterial infections, enabling expedited treatment. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
| Investor contact: | |
| Philip Taylor Gilmartin Group (415) 937-5406 investor@chembio.com |
